Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01975636 · ClinicalTrials.gov registry record · Phase 1
An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects
A Phase 1 study of Metabolism and Elimination, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 113
- Enrollment target
- 2
- Study locations
NCT01975636: Completed Phase 1 study of Metabolism and Elimination, sponsored by Eisai.
NCT01975636 is a Phase 1 study of Metabolism and Elimination that has completed, run by Eisai. The registered enrollment target is 113 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01975636, a Phase 1 study of Metabolism and Elimination, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 113 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open-label, single dose study in healthy male subjects.
Primary Outcome
Total radioactivity will be analyzed in urine and feces predose and up to 28 days postdose.
Conditions Studied
Interventions
- DRUG E2609
Study Locations (2)
Wisconsin
- Covance Clinical Research Unit Inc. - Madison
- Covance Laboratories - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
What the finished NCT01975636 record still lists
NCT01975636 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% higher).
The record links to 1 condition, with Metabolism and Elimination appearing as the primary indexed condition, and to 1 intervention - of which E2609 is the first listed.
NCT01975636 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01975636 about?
NCT01975636 is a clinical study titled "An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects". This is an open-label, single dose study in healthy male subjects.
What is the current status of trial NCT01975636?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2013-06. Estimated completion is 2014-03.
What conditions does trial NCT01975636 study?
This clinical trial studies the following conditions: Metabolism and Elimination.
What interventions are being tested in trial NCT01975636?
The interventions under investigation include: E2609 (DRUG).
Who is sponsoring clinical trial NCT01975636?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01975636 being conducted?
This trial has 2 study locations across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01975636's enrollment target sits among peer trials
113 508th of 2000 higher than 1,493 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia